The measurement of ambulatory impairment in multiple sclerosis

Neurology

Volumn 49, Issue 5, 1997, Pages 1419-1424

  Schwid, Steven R ^a,b   Goodman, A D ^a   Mattson, D H ^a   Mihai, C ^a   Donohoe, K M ^a   Petrie, M D ^a   Scheid, E A ^a   Dudman, J T ^a   McDermott, M P ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Box 605 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; DISABILITY; FEMALE; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; WALKING; WALKING AID;

EID: 0030692770     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.5.1419     Document Type: Article

References (16)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
2. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high-dose cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
3. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114: 1045-1056.
4. Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124.
5. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
6. Schwid SR, Petrie MD, Tierney D, McDermott MP, Goodman AG. Quantitative assessment of sustained-release 4-amino-pyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-821.
7. Poser CM, Paty DW, Scheinberg LW, et al. New diagnostic criteria for MS: guidelines for research protocols. Ann Neurol 1983;13:227-231.
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
9. Kurlan R, McDermott MP. Rating tic severity. In: Kurlan R, ed. Handbook of Tourette's syndrome and related tic and behavioral disorders. New York: Marcel Dekker, 1993:199-220.
10. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40:469-479.
11. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, the Canadian Cooperative MS Study Group. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990;40:971-975.
12. Francis DA, Bain P, Swan AV, Hughes RAC. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 1991;48:299-301.
13. Verdier-Taillefer MH, Zuber M, Lyon-Caen O, et al. Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences. Eur Neurol 1991;31:117-119.
14. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992;42: 859-863.
15. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:655-661.
16. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular Interferon beta 1-a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.